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Bufalin was obtained from the skin and parotid venom glands of toad and has been shown to induce cytotoxic eﬀects in various
types of cancer cell lines, but there is no report to show that whether bufalin aﬀe c t sh u m a ns k i nc a n c e rc e l l s .T h ea i mo ft h i s
investigationwastostudytheeﬀectsofbufalinonhumanmalignantmelanomaA375.S2cellsandtoelucidatepossiblemechanisms
involved in induction of apoptosis. A375.S2 cells were treated with diﬀerent concentrations of bufalin for a speciﬁc time period
and investigated for eﬀects on apoptotic analyses. Our results indicated that cells after exposure to bufalin signiﬁcantly decreased
cell viability, and induced cell morphological changes and chromatin condensation in a concentration-dependent manner.
Flow cytometric assays indicated that bufalin promoted ROS productions, loss of mitochondrial membrane potential (ΔΨm),
intracellular Ca2+ release, and nitric oxide (NO) formations in A375.S2 cells. Additionally, the apoptotic induction of bufalin on
A375.S2 cells resulted from mitochondrial dysfunction-related responses (disruption of the ΔΨm and releases of cytochrome c,
AIF, and Endo G), and activations of caspase-3, caspase-8 and caspase-9 expressions. Based on those observations, we suggest that
bufalin-triggered apoptosis in A375.S2 cells is correlated with extrinsic- and mitochondria-mediated multiple signal pathways.
1.Introduction
Skin cancer is one of the major causes of cancer death
worldwide [1, 2]. Human cutaneous malignant melanoma
is an aggressive skin cancer, and its incidence still continues
to rise in individuals of European origin worldwide [3].
About 4% of all dermatologic cancers are melanoma, but it is
responsible for more than 80% of deaths from skin cancers,2 Evidence-Based Complementary and Alternative Medicine
and patients with metastatic melanoma have a 10-year
survival rate that is less than 10% [4, 5]. It is recognized that
melanoma is highly resistant to conventional chemotherapy,
whichhaspreferentialmetastasistothebrain,lung,liver,and
skin [6, 7]. Currently, the eﬀective cure rate of melanoma has
not been achieved with surgery, radiation, or chemotherapy.
For inhibiting the development of cancer, chemopre-
vention and chemotherapy are commonly used, and those
agents belong to pharmacological or natural agents [8–10].
Chemoprevention has been shown to prevent a wide variety
of cancers in multiple animal models [11]. Natural agents
include antioxidants and cancer preventative agents or even
a c ta sc a n c e rt h e r a p yd r u g s[ 12, 13].
Bufalin, one of the major digoxin-like components, is a
bufadienolide puriﬁed from Chan-Su extracts from the ven-
om of Bufo bufo gargarizan [14, 15], and it has long been
used as a treatment for heart failure in Chinese medicine in
Asian countries [16, 17]. Bufalin acts as a Na+-K+-ATPase
inhibitor for increasing the intracellular Ca2+ concentration
[14, 18] and as a topoisomerase II inhibitor [19, 20]. Bufalin
induced leukemia cell diﬀerentiation and apoptotic death in
prostate cancer cells [21–23], and it inhibited hepatocellular
carcinoma solid tumor growth in vivo [24]. Recently, the
reports have shown that bufalin inhibited cell proliferation
of human lung cancer cells [25] and induced apoptosis of
hepatomaHepG2cells[26].Inourlaboratory,wealsofound
thatbufalinsuppressedthemigrationandinvasionofhuman
osteosarcoma U-2 OS cells by suppression of the matrix
metalloproteinase-2 (MMP-2), extracellular signal-regulated
kinase (ERK), and c-Jun N-terminal kinase (JNK) signaling
pathways[27].However,thereisnoreportregardingbufalin-
induced apoptotic death in human malignant skin cancer
cells invitro.Thepresentstudyinvestigatedbufalin-triggered
cell death in human malignant melanoma A375.S2 cells in
vitro. Due to our observations, the induction of apoptotic
death in A375.S2 cells by bufalin is mediated through
caspase cascade-dependent and independent mitochondrial
signaling pathways.
2.MaterialsandMethods
2.1. Chemicals and Reagents. Bufalin, dimethyl sulfoxide
(DMSO), propidium iodide (PI), RNase A, and Triton X-100
were obtained from the Sigma-Aldrich Corp. (St. Louis,
MO, USA). Minimum essential media (MEM), penicillin-
streptomycin, trypsin-EDTA, fetal bovine serum (FBS) and
theL-glutaminewereobtainedfromGibco/LifeTechnologies
(Carlsbad, CA, USA). 4,6-diamidino-2-phenylindole di-
hydrochloride (DAPI), 2 ,7 -dichlorﬂuorescein-diacetate
(DCFH-DA), 3 ,3-dihexyloxacarbocyanine iodide (DiOC6),
Fluo-3/AM, and 4-amino-5-methylamino-2 ,7 -diﬂuoroﬂu-
orescein diacetate (DAF-FM) were obtained from the Molec-
ularProbes/LifeTechnologies(Eugene,OR,USA).Sourcesof
antibodies used in this study were as follows. Polyclonal anti-
bodies speciﬁc for caspase-3, caspase-8, and caspase-9 were
obtained from the Cell Signaling Technology Inc. (Danvers,
MA, USA). Monoclonal antibodies speciﬁc for cytochrome
c, apoptosis-inducing factors (AIF), Bcl-X, Fas, Fas ligand
(FasL), glucose-regulated protein 78 (GRP78), β-actin, and
horseradish peroxidase- (HRP-) conjugated secondary anti-
bodies were obtained from the Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA). Anti-endonuclease G (Endo G)
(Cat. AB3639) and anti-Bax (Cat. 04-434) were bought from
Merck Millipore (Billerica,MA,USA).
2.2. Cell Culture. The human malignant melanoma cell line
(A375.S2) was purchased from the Food Industry Research
and Development Institute (Hsinchu, Taiwan). About 1 ×
106 cells/mL were maintained in 75cm2 tissue culture ﬂasks
with 90% MEM supplemented with 10% FBS, penicillin-
streptomycin (100U/mL penicillin and 100μg/mL strepto-
mycin), and 2mM L-glutamine and grown at 37◦C in 100%
humidity, 5% CO2, and 95% air [7, 28].
2.3. Assessment of Cell Morphological Changes and Viability.
A375.S2 cells at the density of 2 × 105 cells/well were placed
onto 12-well plates and incubated at 37◦C for 24h before
being treated with or without various concentrations (18.75,
37.5, 75, 150, 250, 350, and 450nM) of bufalin for 24 or 48h.
About0.5%DMSO(solvent)wasusedforthevehiclecontrol
regimen. At the end of incubation, cells were examined and
photographed under contrast phase microscope for mor-
phological changes determination as described elsewhere
[29]. Then cells (1 × 105 cells per sample) were centrifuged
at 1000×g for 5min, and cell pellets were resuspended
with 0.5mL of PBS containing 5μg/mL PI. The viable
cells were determined by a PI-exclusion method and using
a FACSCalibur ﬂow cytometer (BD Biosciences, San Jose,
CA, USA) for determination of viable cells as previously
described [27, 30].
2.4. DAPI Staining for Apoptotic Cells. A375.S2 cells at a
density of 2 × 105 cells/well were placed onto 6-well plates
and treated with bufalin (0, 150, 250, 350, 450, and 550nM)
for24and48hbeforecellsfromeachtreatmentwereisolated
for DAPI staining as described previously [31, 32]. After
staining, the cells were examined and photographed using a
ﬂuorescence microscope at 200x magniﬁcation [33, 34].
2.5. Determinations of the Reactive Oxygen Species (ROS)
Production, the Levels of Mitochondrial Membrane Potential
(ΔΨm), Intracellular Ca2+ Release, and Nitric Oxide (NO)
Generation. A375.S2 cells at a density of 2 × 105 cells/well
onto 12-well plates were exposed to 450nM bufalin for 0, 1,
3, 6, 12, or 24h to determine the changes in the levels of
ROS, ΔΨm, intracellular Ca2+ release, and NO formation,
respectively. Cells were harvested from each treatment then
resuspended in 500μL of DCFH-DA (10μM) for ROS
(H2O2) determination, DiOC6 (1μmol/L) for ΔΨm,F l u o -
3/AM (2.5μg/mL) for intracellular Ca2+ concentrations, and
DAF-FM (a nitric oxide indicator) for NO assessment and
incubated at 37◦Cf o r3 0m i na n dt h e nw e r ea n a l y z e db yﬂ o w
cytometry [29, 34, 35].
2.6. Apoptotic Death-AssociatedProtein Levels Were Examined
by Western Blotting. A375.S2 cells at a density of 1 × 106
A375.S2 cells in 6-well plates were treated with 450nMEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Bufalin aﬀects cells’ morphological changes and reduces percentage of viable A375.S2 cells. Cells were plated onto MEM + 10%
FBS with various concentrations of bufalin for 24 or 48h. (a) The morphological changes were examined and photographed under phase
contrast microscope, and (b) the total percentages of viable cells were determined utilizing a PI-exclusion method and by ﬂow cytometry as
described in Section 2. Each point is mean ± SD of three experiments, ∗P<0.05 was signiﬁcantly diﬀerent from the untreated control.
bufalin for 0, 6, 12, 24, and 48h. Cells were harvested
from each treatment by centrifugation for the total protein
determination as PRO-PREP protein extraction solution
(iNtRON Biotechnology, Seongnam-si, Gyeonggi-do, Korea)
forWesternblotting.Theproteinlevelsofcaspase-3,caspase-
8, caspase-9, cytochrome c,A I F ,E n d oG ,B c l - X ,B a x ,F a s ,
FasL, and GRP78 were examined by using sodium dode-
cylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)
as described previously [34–36]. After electrophoresis, the
proteins were transferred to the Immobilon-P transfer
membrane (Cat. IPVH00010, Merck Millipore) as described
elsewhere [30, 33]. The appropriate horseradish peroxidase-
(HRP-) conjugated secondary antibodies was used to visual-
izebyImmobilonWesternChemiluminescentHRPsubstrate
(Millipore) and X-ray ﬁlm (GE Healthcare, Piscataway, NJ,
USA). The density of bands was quantiﬁed using ImageJ 1.45
program [30].
2.7. Statistical Analysis. The statistical diﬀerences between
the bufalin-treated and control samples were calculated by
Student’s t-test. A value of ∗P<0.05 was considered
signiﬁcant. The quantitative data are shown as mean ± SD.
The results from the in vitro studies are representative of at
least two or three independent experiments.
3. Results
3.1. Bufalin Aﬀects Cell Morphological Changes and Reduces
Percentage of Cell Death in A375.S2 Cells. In order to
investigatethebiologicaleﬀectsofbufalin,A375.S2cellswere
treated with various concentrations of bufalin for 24 and
48h, and cell morphological changes and cell death were
determined. The results are shown in Figures 1(a) and 1(b),
which indicated that bufalin induced morphological changes
(Figure 1(a)) and caused cell death in a concentration-
dependent manner (Figure 1(b)). We found that the half
maximal inhibitory concentration (IC50) is 450.38nM in
bufalin-treated A375.S2 cells at a 48h incubation. Based on
these observations, we selected the concentration of 450nM
bufalin, which is close to IC50, for further assessing whether4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Bufalin induces chromatin condensation and apoptosis in A375.S2 cells. Cells were incubated with various concentrations of
bufalin for 24 (a) and 48h (b). Apoptotic cells were determined by DAPI staining and were photographed at a 200x magniﬁcation under
ﬂuorescence microscopy as described in Section 2. Each experiment was done with triple sets with similar results.
the growth-inhibitory and cell death eﬀects of bufalin are
accompanied by its eﬀect on apoptotic cell death.
3.2. Bufalin Triggers Apoptotic Cell Death in A375.S2 Cells.
In order to conﬁrm if bufalin-induced cell death in A375.S2
cells was through the induction of apoptosis, we used DAPI
staining assay. Results shown in Figures 2(a) and 2(b)
revealed that chromatin condensation and apoptotic cells
were present in bufalin-treated A375.S2 cells for 24 and 48-h
treatments. Moreover, the percentage of apoptotic cells is
calculated (Figure 2) compared with intact control cells and
this eﬀect was concentration dependent.
3.3. Bufalin Aﬀects the Levels of ROS, ΔΨm, and Intracellular
Ca2+ and NO in A375.S2 Cells. I no r d e rt of u r t h e re x a m i n e
whether bufalin-induced apoptotic death is due to aﬀecting
thelevelsofROS,ΔΨm,intracellularCa2+ andNOinA375.S2
cells. Cells were incubated with 450nM bufalin for various
t i m ep e r i o d s .T h el e v e l so fR O Sp r o d u c t i o n ,ΔΨm,a n d
Ca2+ and NO generation were measured by ﬂow cytometric
assay, and these results can be seen in Figure 3. The data
demonstrated that bufalin promoted ROS (Figure 3(a)),
intracellular Ca2+ production (Figure 3(c)), and NO for-
mation (Figure 3(d)) in a time-dependent manner. We also
found that bufalin decreased the levels of ΔΨm in A375.S2
cells at a 24h exposure (Figure 3(b)).
3.4. Bufalin Alters in Apoptotic-Associated Proteins in A375.S2
Cells. To further examine whether or not bufalin induces
apoptosis via alterations of associated protein levels in
A375.S2 cells, cells were treated with 450nM bufalin for 0,
6, 12, 24, and 48h and then were examined by Western
blotting. The results shown in Figure 4 indicated that bufalin
stimulated the expressions of cleaved caspase-3, cleaved
caspase-8, cleaved caspase-9 (Figure 4(a)), cytochrome c,
AIF ,EndoGandBax(Figure 4(b))andFas,FasL,andGRP78
(Figure 4(c)). However, bufalin decreased the expression of
Bcl-XL (Figure 3(b)) in A375.S2 cells.
4. Discussion
Several reports have shown that bufalin inhibited cell growth
viacell cycle arrest and induction of apoptosis in many types
of cancer cell lines [21–26]. However, there is no report to
show that bufalin induced cell death in human melanomaEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Bufalin inﬂuences the levels of reactive oxygen species (ROS), mitochondria membrane potential (ΔΨm), intracellular Ca2+,a n d
nitric oxide (NO) in A375.S2 cells. Cells were incubated with 450nM bufalin for various time periods, before being stained by DCFH-DA
for ROS level (a), by Fluo-3/AM for the intracellular Ca2+ level determined (b), and stained with DiOC6 for the ΔΨm levels (c), or cells
were analyzed for NO production after being stained with DAF-FM (d) by ﬂow cytometric analysis as described in Section 2. Each point is
performed mean ±S.D. and was done in triplicate; ∗P<0.05 was signiﬁcantly diﬀerent from the untreated control.6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Bufalin alters the apoptosis-related protein levels in A375.S2 cells. A total of 1 × 106 A375.S2 cells in 6-well plates were treated
with 450nM bufalin for 0, 6, 12, 24, and 48h. Cells were harvested from each sample and associated proteins were measured by using SDS-
PAGE and Western blotting as described in Section 2. The protein levels of caspase-3, caspase-8, and caspase-9 (a), cytochrome c,A I F ,E n d o
G, Bcl-X, and Bax (b), and Fas, FasL, and GRP78 (c) expressions were examined. β-Actin was used as an internal control to ensure equal
loading.
A375.S2 cells. In the present study, we found that bufalin sig-
niﬁcantly induced cell morphological changes and decreased
the percentage of viable A375.S2 cells (P<0.05) at 24 and
48h(Figures1(a)and1(b)).Furthermore,resultsfromDAPI
staining showed that bufalin induced apoptosis in A375.S2
cells in a concentration-dependent manner (Figures 2(a)
and 2(b)). Although many experiments have showed that
bufalin induced apoptosis in human cancer cell lines, the
molecular mechanism of apoptotic induction in A375.S2
melanoma cells remains unclear. Thus, the present study
further investigated the eﬀect of bufalin on the intrinsic
pathway of apoptosis in A375.S2 cells.
Apoptosis (programmed cell death type I) has been
shown to perform viathe death receptor-dependent pathway
(extrinsic pathway) and mitochondria-dependent pathway
(intrinsic pathway) [37–39]. In death receptor-dependent
pathway, Fas and its receptor Fas ligand (FasL) and caspase-
8 play an important role in regulating the induction of
apoptosis in diverse cell types and tissues [40]. In the
present study, the results from Western blotting (Figure 4(c))
indicated that bufalin promoted the expression of Fas and
FasL and active form of caspase-8 (Figure 4(a)); these data
demonstratedthatbufalininducedapoptosisinA375.S2cells
through the death receptor-dependent pathway (extrinsicEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: A schematic diagram showing the proposed signaling pathways of bufalin-induced apoptosis in A375.S2 human malignant
melanoma cells.
pathway). Figure 4(a) also shows that bufalin promoted the
active form of caspase-3 in a time-dependent manner, which
also indicated that bufalin induced apoptosis of A375.S2
cells via caspase-dependent pathway. It is well documented
that caspase is normally present as an inactive procaspase
b u ti tc a ne x i s ta sac l e a v e df o r mw h e nt r i g g e r e d[ 41, 42].
Those observations are in agreement with other reports
which showed that bufalin induced apoptosis in human
hepatocellular carcinoma cells and human prostate cancer
cells viaFasandFasLpathwayandcaspasepathways[17,26].
Results from ﬂow cytometric assay showed that bufalin
decreased the levels of ΔΨm (Figure 3(b)). Furthermore,
Figure 4(b) indicates that bufalin promoted the levels of
cytochrome c, AIF, Endo G, and Bax but inhibited the Bcl-XL
expression in A375.S2 cells. Bcl-2 family proteins have been
shown to regulate the mitochondria-dependent pathway and
death receptor-dependent pathway [43, 44]. Bcl-2 family
proteins include the proapoptotic proteins such as Bax, Bak,
Bad, and Bcl-Xs and the antiapoptotic proteins such as Bcl-
2, Bcl-XL, and Mcl-1 [45]. The ratio of Bax/Bcl-2 aﬀects the
levels of ΔΨm in cells after exposure to inducer of apoptosis
[45], and then mitochondrial release of cytochrome c can be
controlled by the ratio of Bax/Bcl-2 proteins and activated by
proteolytic cleavage and heterodimerization [46]. Based on
those observations, we suggest that bufalin-induced apopto-
sis in A375.S2 cells was partly through the mitochondria-
as well as caspase-dependent and independent pathways.
Overall, bufalin induced apoptosis in A375.S2 cells through
cross-talk between the extrinsic and the intrinsic pathways.
In conclusion, we proposed the possible signaling pathway
of bufalin-induced apoptosis in A375.S2 cells that is shown
in Figure 5. The possible ﬂow chart indicated that bufalin
triggers apoptosis via Fas/FasL, caspase cascade (caspase-3,
8 and 9) or the loss of ΔΨm in mitochondria and then led to
AIF and Endo G release that is a novel ﬁnding for bufalin-
induced apoptosis in A375.S2 cells. These results provided a
novel and more detailed molecular mechanism in bufalin-
induced apoptosis in A375.S2 cells in vitro.
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